FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079294175> ?p ?o ?g. }

• W2079294175 endingPage "23" @default.
• W2079294175 startingPage "15" @default.
• W2079294175 abstract "Surgical bypass of peripheral arterial occlusive disease with autologous vein grafts provides an effective means of restoring blood flow to the lower extremity, and has been a standard therapy for patients with disabling claudication or critical limb ischemia (CLI). However, failure rates may run as high as 50% within 5 years. These graft failures occur as a result of neointimal hyperplasia, a ubiquitous biologic response of blood vessel walls to injury, which is characterized by the migration and proliferation of smooth muscle cells (SMC). The E2F family of transcription factors regulates the expression of genes controlling SMC proliferation. Edifoligide (E2F Decoy) is a novel therapy that inhibits E2F function, thus attenuating neointimal hyperplasia. Its use in conjunction with a patented drug delivery pressurization chamber is under investigation. Using this system, edifoligide is administered to vein grafts in a single, ex vivo treatment following vein harvest and before implantation, resulting in minimal systemic drug exposure and excellent patient compliance. This Phase 3, randomized, double-blind, multicenter clinical trial is designed to evaluate the safety and efficacy of edifoligide in a population of approximately 1400 patients with CLI undergoing infrainguinal bypass for peripheral arterial disease (PAD). The primary outcome measure will be the time to occurrence of non-technical graft failure resulting in either graft revision or major amputation at 12 months after enrollment. A governing Clinical Events Classification committee (CEC) will adjudicate each graft failure to determine its etiology. The PREVENT III trial is the largest multicenter trial ever performed in patients receiving autologous vein bypass grafts for CLI. This landmark study will determine if edifoligide is safe and effective at preventing vein graft failure in patients undergoing lower extremity bypass, but it also provides a unique opportunity to observe current treatment practices in vascular surgery." @default.
• W2079294175 created "2016-06-24" @default.
• W2079294175 creator A5016520112 @default.
• W2079294175 creator A5028040379 @default.
• W2079294175 creator A5064950593 @default.
• W2079294175 creator A5076128617 @default.
• W2079294175 creator A5077386792 @default.
• W2079294175 creator A5089291181 @default.
• W2079294175 date "2005-01-01" @default.
• W2079294175 modified "2023-10-09" @default.
• W2079294175 title "Design and Rationale of the PREVENT III Clinical Trial: Edifoligide for the Prevention of Infrainguinal Vein Graft Failure" @default.
• W2079294175 cites W1989169142 @default.
• W2079294175 cites W1992346069 @default.
• W2079294175 cites W2000958015 @default.
• W2079294175 cites W2014754618 @default.
• W2079294175 cites W2028316845 @default.
• W2079294175 cites W2035413582 @default.
• W2079294175 cites W2070946600 @default.
• W2079294175 cites W2076301763 @default.
• W2079294175 cites W2110029160 @default.
• W2079294175 cites W2155681330 @default.
• W2079294175 cites W2344256737 @default.
• W2079294175 cites W2426717210 @default.
• W2079294175 cites W4240324227 @default.
• W2079294175 doi "https://doi.org/10.1177/153857440503900102" @default.
• W2079294175 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1448169" @default.
• W2079294175 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15696244" @default.
• W2079294175 hasPublicationYear "2005" @default.
• W2079294175 type Work @default.
• W2079294175 sameAs 2079294175 @default.
• W2079294175 citedByCount "54" @default.
• W2079294175 countsByYear W20792941752012 @default.
• W2079294175 countsByYear W20792941752013 @default.
• W2079294175 countsByYear W20792941752014 @default.
• W2079294175 countsByYear W20792941752015 @default.
• W2079294175 countsByYear W20792941752016 @default.
• W2079294175 countsByYear W20792941752017 @default.
• W2079294175 countsByYear W20792941752019 @default.
• W2079294175 countsByYear W20792941752020 @default.
• W2079294175 countsByYear W20792941752021 @default.
• W2079294175 countsByYear W20792941752022 @default.
• W2079294175 crossrefType "journal-article" @default.
• W2079294175 hasAuthorship W2079294175A5016520112 @default.
• W2079294175 hasAuthorship W2079294175A5028040379 @default.
• W2079294175 hasAuthorship W2079294175A5064950593 @default.
• W2079294175 hasAuthorship W2079294175A5076128617 @default.
• W2079294175 hasAuthorship W2079294175A5077386792 @default.
• W2079294175 hasAuthorship W2079294175A5089291181 @default.
• W2079294175 hasBestOaLocation W20792941752 @default.
• W2079294175 hasConcept C126322002 @default.
• W2079294175 hasConcept C141071460 @default.
• W2079294175 hasConcept C2776204877 @default.
• W2079294175 hasConcept C2777466421 @default.
• W2079294175 hasConcept C2778095995 @default.
• W2079294175 hasConcept C2778283817 @default.
• W2079294175 hasConcept C2778583881 @default.
• W2079294175 hasConcept C2778963770 @default.
• W2079294175 hasConcept C2779751240 @default.
• W2079294175 hasConcept C2781099653 @default.
• W2079294175 hasConcept C2908647359 @default.
• W2079294175 hasConcept C2992686903 @default.
• W2079294175 hasConcept C3018348675 @default.
• W2079294175 hasConcept C535046627 @default.
• W2079294175 hasConcept C71924100 @default.
• W2079294175 hasConcept C99454951 @default.
• W2079294175 hasConceptScore W2079294175C126322002 @default.
• W2079294175 hasConceptScore W2079294175C141071460 @default.
• W2079294175 hasConceptScore W2079294175C2776204877 @default.
• W2079294175 hasConceptScore W2079294175C2777466421 @default.
• W2079294175 hasConceptScore W2079294175C2778095995 @default.
• W2079294175 hasConceptScore W2079294175C2778283817 @default.
• W2079294175 hasConceptScore W2079294175C2778583881 @default.
• W2079294175 hasConceptScore W2079294175C2778963770 @default.
• W2079294175 hasConceptScore W2079294175C2779751240 @default.
• W2079294175 hasConceptScore W2079294175C2781099653 @default.
• W2079294175 hasConceptScore W2079294175C2908647359 @default.
• W2079294175 hasConceptScore W2079294175C2992686903 @default.
• W2079294175 hasConceptScore W2079294175C3018348675 @default.
• W2079294175 hasConceptScore W2079294175C535046627 @default.
• W2079294175 hasConceptScore W2079294175C71924100 @default.
• W2079294175 hasConceptScore W2079294175C99454951 @default.
• W2079294175 hasIssue "1" @default.
• W2079294175 hasLocation W20792941751 @default.
• W2079294175 hasLocation W20792941752 @default.
• W2079294175 hasLocation W20792941753 @default.
• W2079294175 hasLocation W20792941754 @default.
• W2079294175 hasOpenAccess W2079294175 @default.
• W2079294175 hasPrimaryLocation W20792941751 @default.
• W2079294175 hasRelatedWork W1972258680 @default.
• W2079294175 hasRelatedWork W1982173900 @default.
• W2079294175 hasRelatedWork W1997445984 @default.
• W2079294175 hasRelatedWork W2046785089 @default.
• W2079294175 hasRelatedWork W2140350804 @default.
• W2079294175 hasRelatedWork W2142938542 @default.
• W2079294175 hasRelatedWork W2360642739 @default.
• W2079294175 hasRelatedWork W2419327623 @default.
• W2079294175 hasRelatedWork W2735536570 @default.
• W2079294175 hasRelatedWork W2919307241 @default.

• next